San Diego-based mostly Viking Therapeutics marked itself as a serious competitor in the weight loss drug market place in February after revealing promising data from the mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection As well as in March the company